Servier has nine glioma abstracts for SNO 2026, but can the data expand its treatment reach?
Servier reveals its SNO 2026 plans for Voranigo and Ojemda, with long-term glioma outcomes, treatment durability and potential expansion in focus.
Pharma & Biotech